4 minutes to read

What's going on with Danish stocks?

Peter Garnry

Head of Equity Strategy

Summary:  A localized earthquake of negative headlines has shaken the share prices of some of Denmark's largest companies today. The timing is coincidental but the impact, with Copenhagen down 3.6% as of this writing, is very real.


On this slight down day in global equities (-0.4%)  a financial earthquake is taken place in a small corner of the equity market. The leading Danish benchmark index on equities, the OMXC25, is down 3.6% driven by a bunch of company-specific headlines hitting several companies on the same day.

It is ultimately a coincidence, but nevertheless represents obvious pain for investors in this market. It is particularly painful as the OMXC25 has been one of the best markets for years, awakening foreign interest in this tiny little equity market.

Let’s look at some of today’s events:

• Novo Nordisk shares are down 9% (biggest index weight at 15.4%) as Eli Lilly has announced test results for an experimental diabetes drug to cut patients’ weight and reduce blood-sugar levels. If Eli Lilly pushes new drugs forward with these benefits it would threaten Novo Nordisk’s current position in this market.

• Danske Bank shares are down 4% as the US Department of Justice is now investigating the money laundering case. This follows similar moves in Denmark and Estonia, adding to the negative sentiment on Denmark’s largest bank.

• Ambu shares are down 15% as the new financial targets for FY'20 are disappointing the market. The shares are now down 50% from the peak in August as the previous investor darling has seen its price target being cut by several sell-side analysts with investor concerns over management only bolstering the sell-off. Ambu was not long ago priced at the same valuation (on free cash flow yield) as Amazon, indicating strong investor confidence, but now it seems investors are having second thoughts.


The fact that these things are all happening on the same day isa, of course, random. Danish equities are still of high quality relative to global equities overall, but sentiment is definitely negative with key technical levels being broken today.

Outside of Denmark, our view continues to be defensive on equities. US stocks are becoming outright unattractive as US credit offers a better risk-reward deal for investors. It is absolutely confusing to us to see new highs in US equities will the house of cards in emerging markets is collapsing. The escalating trade war resembles a new cold war between the US and China, and is worrying to say it the least.

European banks are weak and Italy looks like a time bomb ready to go off. Meanwhile, the complacency is staggering with volatility still low given the risks on the horizon. We cannot state it enough how important it is for investors to set up their portfolios for more turbulence as 2019 approaches.

You can access both of our platforms from a single Saxo account.

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)